A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the way and rate that the study medication, JSM6427
a potent, highly specific integrin α5β1-antagonist is absorbed, broken-down and eliminated
from the body when it is given as a single dosage strength by injection into the eye.
Repeated dosages will also be given to determine the highest safe dose.